HomeCompareVRCDF vs VYM

VRCDF vs VYM: Dividend Comparison 2026

VRCDF yields 66666.67% · VYM yields 2.41%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 VRCDF wins by $8.441837856534449e+24M in total portfolio value
10 years
VRCDF
VRCDF
● Live price
66666.67%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$8.441837856534449e+24M
Annual income
$8,417,001,582,403,749,000,000,000,000,000.00
Full VRCDF calculator →
VYM
Vanguard High Dividend Yield ETF
● Live price
2.41%
Share price
$145.48
Annual div
$3.51
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$27.8K
Annual income
$278.55
Full VYM calculator →

Portfolio growth — VRCDF vs VYM

📍 VRCDF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodVRCDFVYM
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, VRCDF + VYM cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
VRCDF pays
VYM pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

VRCDF
Annual income on $10K today (after 15% tax)
$5,666,666.67/yr
After 10yr DRIP, annual income (after tax)
$7,154,451,345,043,187,000,000,000,000,000.00/yr
VYM
Annual income on $10K today (after 15% tax)
$205.23/yr
After 10yr DRIP, annual income (after tax)
$236.77/yr
At 15% tax rate, VRCDF beats the other by $7,154,451,345,043,187,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of VRCDF + VYM for your $10,000?

VRCDF: 50%VYM: 50%
100% VYM50/50100% VRCDF
Portfolio after 10yr
$4.2209189282672247e+24M
Annual income
$4,208,500,791,201,874,400,000,000,000,000.00/yr
Blended yield
99.71%
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

VRCDF buys
0
VYM buys
0
No recent congressional trades found for VRCDF or VYM in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricVRCDFVYM
Forward yield66666.67%2.41%
Annual dividend / share$2.00$3.51
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$8.441837856534449e+24M$27.8K
Annual income after 10y$8,417,001,582,403,749,000,000,000,000,000.00$278.55
Total dividends collected$8.44020886744369e+24M$2.6K
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: VRCDF vs VYM ($10,000, DRIP)

YearVRCDF PortfolioVRCDF Income/yrVYM PortfolioVYM Income/yrGap
1← crossover$6,677,367$6,666,666.67$11,151$241.44+$6.67MVRCDF
2$4,167,497,846$4,160,353,063.34$12,413$246.79+$4167.49MVRCDF
3$2,431,161,901,635$2,426,702,678,939.67$13,794$251.79+$2431161.89MVRCDF
4$1,325,636,209,022,888$1,323,034,865,788,139.00$15,306$256.47+$1325636209.01MVRCDF
5$675,632,775,263,916,700$674,214,344,520,262,300.00$16,960$260.84+$675632775263.90MVRCDF
6$321,867,481,182,444,260,000$321,144,554,112,911,900,000.00$18,768$264.92+$321867481182444.25MVRCDF
7$143,326,993,661,751,470,000,000$142,982,595,456,886,240,000,000.00$20,745$268.71+$143326993661751472.00MVRCDF
8$59,657,925,421,851,500,000,000,000$59,504,565,538,633,426,000,000,000.00$22,905$272.24+$59657925421851500544.00MVRCDF
9$23,211,471,150,187,795,000,000,000,000$23,147,637,169,986,416,000,000,000,000.00$25,265$275.51+$2.3211471150187796e+22MVRCDF
10$8,441,837,856,534,450,000,000,000,000,000$8,417,001,582,403,749,000,000,000,000,000.00$27,842$278.55+$8.441837856534449e+24MVRCDF

VRCDF vs VYM: Complete Analysis 2026

VRCDFStock

Verici Dx plc, an immuno-diagnostics development company, focuses on the kidney transplantation market. The company develops prognostic and diagnostic tests for kidney transplant patients. Its in-development tests include Clarava, a pre-transplant prognosis test for the risk of early acute rejection; Tuteva, a post-transplant test that focuses on acute cellular rejection; and Protega, a liquid biopsy that aims to predict the risk of fibrosis and long-term graft failure. The company was incorporated in 2020 and is based in Penarth, the United Kingdom.

Full VRCDF Calculator →

VYMETF

Seeks to track the performance of the FTSE High Dividend Yield Index, which measures the investment return of common stocks of companies characterized by high dividend yields. Provides a convenient way to track the performance of stocks that are forecasted to have above-average dividend yields. Follows a passively managed, full-replication approach.

Full VYM Calculator →
📬

Get this VRCDF vs VYM comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

VRCDF vs SCHDVRCDF vs JEPIVRCDF vs OVRCDF vs KOVRCDF vs MAINVRCDF vs VIGVRCDF vs DGROVRCDF vs HDV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.